Oruka Therapeutics registers Phase 2 study of ORKA-002 in hidradenitis suppurativa

Oruka Therapeutics had one item posted this week involving a new Phase 2 registration for its drug ORKA-002.

• ORKA-002, a subcutaneous injection, is being tested against placebo in a Phase 2 study for adults with moderate-to-severe hidradenitis suppurativa. The trial is recruiting, with an actual start date of August 21, 2026, and was first posted August 24, 2026.¹ The study plans to enroll 200 participants and the primary outcome is the proportion of participants achieving HiSCR75 at Week 16¹, defined as at least a 75% reduction from Baseline in the total abscess and inflammatory nodule count, with no increase from Baseline in abscess or draining tunnel count¹.